World Investment Advisors Sells 4,780 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

World Investment Advisors cut its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 25.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,777 shares of the biotechnology company’s stock after selling 4,780 shares during the period. World Investment Advisors’ holdings in Arrowhead Pharmaceuticals were worth $218,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Moody Lynn & Lieberson LLC purchased a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth about $213,000. Hsbc Holdings PLC bought a new position in Arrowhead Pharmaceuticals in the 1st quarter worth about $173,000. CWM LLC boosted its stake in Arrowhead Pharmaceuticals by 159.4% in the 2nd quarter. CWM LLC now owns 11,415 shares of the biotechnology company’s stock worth $180,000 after purchasing an additional 7,014 shares during the period. GAMMA Investing LLC boosted its stake in Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,628 shares during the period. Finally, New York State Teachers Retirement System boosted its position in shares of Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. New York State Teachers Retirement System now owns 148,376 shares of the biotechnology company’s stock valued at $1,890,000 after acquiring an additional 9,593 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $40.31 on Thursday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $43.69. The stock has a market capitalization of $5.57 billion, a PE ratio of -31.49 and a beta of 1.27. The stock’s 50 day moving average price is $33.71 and its 200-day moving average price is $22.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analysts’ expectations of $29.01 million. During the same quarter in the previous year, the business earned ($1.38) earnings per share. On average, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Activity

In other news, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the transaction, the insider directly owned 212,122 shares of the company’s stock, valued at approximately $7,424,270. The trade was a 8.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 60,000 shares of company stock worth $1,725,000 over the last 90 days. 4.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Royal Bank Of Canada dropped their price target on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. TD Cowen upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, July 28th. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 18th. B. Riley upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 11th. Finally, Chardan Capital restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.